NCT06037954 A Study of Mental Health Care in People With Cancer
| NCT ID | NCT06037954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2023-09-07 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2023-09-07 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.
Eligibility Criteria
Inclusion Criteria: Patients * Per medical record and/or self-report, diagnosed with breast, colorectal, lung, or prostate cancer at age 65 years or older * Per medical record and/or self-report, undergoing active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, surgery) or within six months of completing treatment * Score of ≥5 on the Patient Health Questionnaire-9 (PHQ-9) * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English) Providers * Per self-report, works in oncology, nursing, social work, psychology, or psychiatry * Per self-report, currently works in oncology at least 50% of the time * Per self-report, provided cancer care for at least three years at time of consent * Per self-report, fluent in English Exclusion Criteria: Patients * Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration scores of ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures * Per medical record and/or self-report, receiving hospice care at the time of enrollment * Per medical record and/or self-report, currently enrolled in mental health treatment Providers * N/A
Contact & Investigator
Kelly McConnell, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT06037954 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06037954 currently recruiting?
Yes, NCT06037954 is actively recruiting participants. Contact the research team at mcconnek@mskcc.org for enrollment information.
Where is the NCT06037954 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06037954 clinical trial?
NCT06037954 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Kelly McConnell, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.